文献速递肾小球疾病

经活检证实的微小病变肾病的发病年龄与病程:Cure肾小球肾病网络分析

Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network.
PubMed 文献 · Am J Kidney Dis · 2023-01-03

CureGN前瞻性多中心观察研究纳入304例儿童期、49例青少年期和201例成人期发病的经活检证实的微小病变肾病患者,随访2.7-3.2年。儿童期发病者复发率更高(HR 1.69),但缓解概率也更高(HR 1.33);儿童期发病者接受利妥昔单抗后缓解可能性高于青少年和成人期发病者(校正HR 2.1)。

要点

  • 儿童期发病微小病变肾病复发率高于成人期发病(HR 1.69,95%CI 1.29-2.21)。
  • 儿童期发病缓解概率也高于成人期发病(HR 1.33,95%CI 1.02-1.72)。
  • 儿童期发病者利妥昔单抗后缓解可能性更高(校正HR 2.1,P=0.003)。

核心结论

  • 在接受肾活检的微小病变肾病患者中,儿童期发病与青少年期和成人期发病在病程(复发和缓解)及利妥昔单抗反应方面存在差异。

研究设计与样本

  • 前瞻性、多中心、观察性研究,纳入CureGN中经活检证实的微小病变肾病患者。
  • 共纳入304例儿童期(≤12岁)、49例青少年期(13-17岁)和201例成人期(≥18岁)发病参与者,入组后随访2.7-3.2年。

主要发现

  • 儿童期发病者从发病到活检时间更长(238天 vs 青少年期23天和成人期36天,P<0.001),且更可能在活检前接受治疗。
  • 儿童期发病者更可能接受免疫抑制治疗,但RAAS阻断无此差异。
  • 儿童期发病者复发率高于成人期发病者(HR 1.69,95%CI 1.29-2.21)。
  • 儿童期发病者缓解概率也高于成人期发病者(HR 1.33,95%CI 1.02-1.72);所有组eGFR下降均轻微。
  • 儿童期发病者接受利妥昔单抗后缓解可能性高于青少年期或成人期发病者(校正HR 2.1,P=0.003);所有组中糖皮质激素敏感与利妥昔单抗后完全缓解可能性更高相关(校正HR 2.62,P=0.002)。

局限性

  • CureGN仅限于经活检证实的疾病。
  • 儿童期与非儿童期微小病变肾病的比较可能存在选择偏倚,因为接受活检的儿童期病例可能仅限于对初始治疗反应最差的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Adolescent- and adult-onset minimal change disease (MCD) may have a clinical course distinct from childhood-onset disease. We characterized the course of children and adults with MCD in the Cure Glomerulonephropathy Network (CureGN) and assessed predictors of rituximab response. STUDY DESIGN: Prospective, multicenter, observational study. STUDY PARTICIPANTS: CureGN participants with proven MCD on biopsy. EXPOSURE: Age at disease onset, initiation of renin-angiotensin-aldosterone system (RAAS) blockade, and immunosuppression including rituximab during the study period. OUTCOME: Relapse and remission, change in estimated glomerular filtration rate (eGFR), and kidney failure. ANALYTICAL APPROACH: Remission and relapse probabilities were estimated using Kaplan-Meier curves and gap time recurrent event models. Linear regression models were used for the outcome of change in eGFR. Cox proportional hazards models were used to estimate the association between rituximab administration and remission. RESULTS: The study included 304 childhood- (≤12 years old), 49 adolescent- (13-17 years old), and 201 adult- (≥18 years) onset participants with 2.7-3.2 years of follow-up after enrollment. Children had a longer time to biopsy (238 vs 23 and 36 days in adolescent- and adult-onset participants, respectively; P<0.001) and were more likely to have received therapy before biopsy. Children were more likely to be treated with immunosuppression but not RAAS blockade. The rate of relapse was higher in childhood- versus adult-onset participants (HR, 1.69 [95% CI, 1.29-2.21]). The probability of remission was also higher in childhood-onset disease (HR, 1.33 [95%CI, 1.02-1.72]). In all groups eGFR loss was minimal. Children were more likely to remit after rituximab than those with adolescent- or adult-onset disease (adjusted HR, 2.1; P=0.003). Across all groups, glucocorticoid sensitivity was associated with a greater likelihood of achieving complete remission after rituximab (adjusted HR, 2.62; P=0.002). LIMITATIONS: CureGN was limited to biopsy-proven disease. Comparisons of childhood to nonchildhood cases of MCD may be subject to selection bias, given that childhood cases who undergo a biopsy may be limited to patients who are least responsive to initial therapy. CONCLUSIONS: Among patients with MCD who underwent kidney biopsy, there were differences in the course (relapse and remission) of childhood-onset compared with adolescent- and adult-onset disease, as well as rituximab response. PLAIN-LANGUAGE SUMMARY: Minimal change disease is a biopsy diagnosis for nephrotic syndrome. It is diagnosed in childhood, adolescence, or adulthood. Patients and clinicians often have questions about what to expect in the disease course and how to plan therapies. We analyzed a group of patients followed longitudinally as part of the Cure Glomerulonephropathy Network (CureGN) and describe the differences in disease (relapse and remission) based on the age of onset. We also analyzed rituximab response. We found that those with childhood-onset disease had a higher rate of relapse but also have a higher probability of reaching remission when compared with adolescent- or adult-onset disease. Children and all steroid-responsive patients are more likely to achieve remission after rituximab.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Chen DP, Helmuth ME, Smith AR, et al. Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network. Am J Kidney Dis. 2023. PMID: 36608921. doi:10.1053/j.ajkd.2022.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。